

Magnus Sjogren

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8167374/publications.pdf>

Version: 2024-02-01

117
papers

8,727
citations

44042

48
h-index

42364

92
g-index

121
all docs

121
docs citations

121
times ranked

10299
citing authors

#	ARTICLE	IF	CITATIONS
1	A New Rating Scale for Age-Related White Matter Changes Applicable to MRI and CT. <i>Stroke</i> , 2001, 32, 1318-1322.	1.0	1,506
2	Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. <i>Neuroscience Letters</i> , 2000, 285, 49-52.	1.0	452
3	Measurement of Phosphorylated Tau Epitopes in the Differential Diagnosis of Alzheimer Disease. <i>Archives of General Psychiatry</i> , 2004, 61, 95.	13.8	390
4	High total cholesterol levels in late life associated with a reduced risk of dementia. <i>Neurology</i> , 2005, 64, 1689-1695.	1.5	346
5	Increased intrathecal levels of the angiogenic factors VEGF and TGF- β 2 in Alzheimer's disease and vascular dementia. <i>Neurobiology of Aging</i> , 2002, 23, 237-243.	1.5	329
6	The future of blood-based biomarkers for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 115-131.	0.4	250
7	Cytosolic free calcium elevation mediates the phagosome-lysosome fusion during phagocytosis in human neutrophils. <i>Journal of Cell Biology</i> , 1990, 110, 1555-1564.	2.3	235
8	CSF levels of tau, β -amyloid 1-42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. <i>Journal of Neural Transmission</i> , 2000, 107, 563-579.	1.4	227
9	Treatment of Alzheimer's Disease with Clioquinol. <i>Dementia and Geriatric Cognitive Disorders</i> , 2001, 12, 408-414.	0.7	202
10	Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients. <i>NeuroReport</i> , 2002, 13, 611-615.	0.6	190
11	Neurofilament protein in cerebrospinal fluid: A marker of white matter changes. <i>Journal of Neuroscience Research</i> , 2001, 66, 510-516.	1.3	175
12	Cognition-Enhancing Effect of Vagus Nerve Stimulation in Patients With Alzheimer's Disease. <i>Journal of Clinical Psychiatry</i> , 2002, 63, 972-980.	1.1	170
13	Vagus Nerve Stimulation in Patients With Alzheimer's Disease. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 1171-1178.	1.1	165
14	Decreased cerebrospinal fluid neuropeptide Y (NPY) in patients with treatment refractory unipolar major depression: preliminary evidence for association with preproNPY gene polymorphism. <i>Journal of Psychiatric Research</i> , 2004, 38, 113-121.	1.5	161
15	The Goteborg MCI study: mild cognitive impairment is a heterogeneous condition. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 76, 1485-1490.	0.9	156
16	Developing novel blood-based biomarkers for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 109-114.	0.4	138
17	Decreased CSF- β -Amyloid 42 in Alzheimer's Disease and Amyotrophic Lateral Sclerosis May Reflect Mismetabolism of β -Amyloid Induced by Disparate Mechanisms. <i>Dementia and Geriatric Cognitive Disorders</i> , 2002, 13, 112-118.	0.7	125
18	The Cerebrospinal Fluid Amyloid β 42/40 Ratio in the Differentiation of Alzheimer's Disease from Non-Alzheimer's Dementia. <i>Current Alzheimer Research</i> , 2010, 7, 470-476.	0.7	120

#	ARTICLE	IF	CITATIONS
19	Measurement of β - and β -secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients. <i>Experimental Neurology</i> , 2003, 183, 74-80.	2.0	114
20	CSF markers for Alzheimer's disease: Total tau, phospho-tau and β 42. <i>World Journal of Biological Psychiatry</i> , 2003, 4, 147-155.	1.3	108
21	The Cerebrospinal Fluid Levels of Tau, Growth-Associated Protein-43 and Soluble Amyloid Precursor Protein Correlate in Alzheimer's Disease, Reflecting a Common Pathophysiological Process. <i>Dementia and Geriatric Cognitive Disorders</i> , 2001, 12, 257-264.	0.7	102
22	Treatment with Simvastatin in Patients with Alzheimer's Disease Lowers Both β - and β -Cleaved Amyloid Precursor Protein. <i>Dementia and Geriatric Cognitive Disorders</i> , 2003, 16, 25-30.	0.7	102
23	The exfoliation syndrome in cognitive impairment of cerebrovascular or Alzheimer's type. <i>Acta Ophthalmologica</i> , 2001, 79, 283-285.	0.4	95
24	Studies of the pathophysiological mechanisms in frontotemporal dementia by proteome analysis of CSF proteins. <i>Molecular Brain Research</i> , 2002, 109, 128-133.	2.5	95
25	Structural and Quantitative Comparison of Cerebrospinal Fluid Glycoproteins in Alzheimer's Disease Patients and Healthy Individuals. <i>Neurochemical Research</i> , 2008, 33, 1332-1340.	1.6	95
26	The Use of Proteomics in Biomarker Discovery in Neurodegenerative Diseases. <i>Disease Markers</i> , 2005, 21, 81-92.	0.6	90
27	Cerebrospinal Fluid β -Synuclein Does Not Discriminate Between Dementia Disorders. <i>Journal of Alzheimer's Disease</i> , 2009, 16, 363-369.	1.2	87
28	The Effect of Simvastatin Treatment on the Amyloid Precursor Protein and Brain Cholesterol Metabolism in Patients with Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2005, 19, 256-265.	0.7	86
29	Cholesterol and Alzheimer's disease— is there a relation?. <i>Mechanisms of Ageing and Development</i> , 2006, 127, 138-147.	2.2	86
30	Symptoms, Vascular Risk Factors and Blood-Brain Barrier Function in Relation to CT White-Matter Changes in Dementia. <i>European Neurology</i> , 2000, 44, 229-235.	0.6	85
31	Stepwise Comparative Status Analysis (STEP): A Tool for Identification of Regional Brain Syndromes in Dementia. <i>Journal of Geriatric Psychiatry and Neurology</i> , 1996, 9, 185-199.	1.2	84
32	Decreased monoamine metabolites in frontotemporal dementia and Alzheimer's disease. <i>Neurobiology of Aging</i> , 1998, 19, 379-384.	1.5	80
33	Small heat shock proteins Hsp27 or β -crystallin and the protein components of neurofibrillary tangles: Tau and neurofilaments. <i>Journal of Neuroscience Research</i> , 2008, 86, 1343-1352.	1.3	73
34	Low cerebrospinal fluid β -amyloid 42 in patients with acute bacterial meningitis and normalization after treatment. <i>Neuroscience Letters</i> , 2001, 314, 33-36.	1.0	71
35	Clinic-Based Cases with Frontotemporal Dementia Show Increased Cerebrospinal Fluid Tau and High Apolipoprotein E ϵ 4 Frequency, but No Tau Gene Mutations. <i>Experimental Neurology</i> , 2001, 168, 413-418.	2.0	70
36	Altered levels of cerebrospinal fluid reelin in frontotemporal dementia and Alzheimer's disease. <i>Journal of Neuroscience Research</i> , 2003, 72, 132-136.	1.3	69

#	ARTICLE	IF	CITATIONS
37	Frontotemporal Dementia Can Be Distinguished from Alzheimer's Disease and Subcortical White Matter Dementia by an Anterior-to-Posterior rCBF-SPET Ratio. <i>Dementia and Geriatric Cognitive Disorders</i> , 2000, 11, 275-285.	0.7	60
38	Glycine Transporter Inhibitor Attenuates the Psychotomimetic Effects of Ketamine in Healthy Males: Preliminary Evidence. <i>Neuropsychopharmacology</i> , 2012, 37, 1036-1046.	2.8	58
39	Advances in the detection of Alzheimer's disease—use of cerebrospinal fluid biomarkers. <i>Clinica Chimica Acta</i> , 2003, 332, 1-10.	0.5	57
40	The apolipoprotein E ϵ 4 allele frequency is normal in fronto-temporal dementia, but correlates with age at onset of disease. <i>Neuroscience Letters</i> , 1997, 226, 65-67.	1.0	55
41	Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's disease. <i>Journal of Neuroscience Research</i> , 2003, 72, 520-526.	1.3	55
42	Assessments of the accumulation severities of amyloid β -protein and hyperphosphorylated tau in the medial temporal cortex of control and Alzheimer's brains. <i>Neurobiology of Disease</i> , 2006, 22, 657-668.	2.1	55
43	The link between cholesterol and Alzheimer's disease. <i>World Journal of Biological Psychiatry</i> , 2005, 6, 85-97.	1.3	54
44	Cerebrospinal fluid cytoskeleton proteins in patients with subcortical white-matter dementia. <i>Mechanisms of Ageing and Development</i> , 2001, 122, 1937-1949.	2.2	51
45	Selective reduction of soluble Tau proteins in sporadic and familial frontotemporal dementias: an international follow-up study. <i>Acta Neuropathologica</i> , 2003, 105, 469-476.	3.9	51
46	Secular changes in cognitive predictors of dementia and mortality in 70-year-olds. <i>Neurology</i> , 2010, 75, 779-785.	1.5	51
47	Tacrine and rate of progression in Alzheimer's disease—relation to ApoE allele genotype. <i>Journal of Neural Transmission</i> , 2001, 108, 451-458.	1.4	50
48	Apathy is a prominent neuropsychiatric feature of radiological white-matter changes in patients with dementia. <i>International Journal of Geriatric Psychiatry</i> , 2010, 25, 588-595.	1.3	50
49	Validation of a prefractionation method followed by two-dimensional electrophoresis - Applied to cerebrospinal fluid proteins from frontotemporal dementia patients. <i>Proteome Science</i> , 2004, 2, 7.	0.7	45
50	Altered kallikrein 7 and 10 concentrations in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. <i>Clinical Biochemistry</i> , 2004, 37, 230-237.	0.8	43
51	Cerebrospinal fluid neuropeptides in Alzheimer's disease and vascular dementia. <i>Biological Psychiatry</i> , 1995, 38, 210-216.	0.7	42
52	Decreased Cerebrospinal Fluid Acetylcholinesterase in Patients with Subcortical Ischemic Vascular Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2003, 16, 200-207.	0.7	41
53	Neurofibrillary degeneration in Alzheimer's disease: from molecular mechanisms to identification of drug targets. <i>Current Opinion in Psychiatry</i> , 2008, 21, 555-561.	3.1	41
54	SYMPTOMATOLOGICAL CHARACTERISTICS DISTINGUISH BETWEEN FRONTOTEMPORAL DEMENTIA AND VASCULAR DEMENTIA WITH A DOMINANT FRONTAL LOBE SYNDROME. <i>International Journal of Geriatric Psychiatry</i> , 1997, 12, 656-661.	1.3	40

#	ARTICLE	IF	CITATIONS
55	Proteome studies of CSF in AD patients. <i>Mechanisms of Ageing and Development</i> , 2006, 127, 133-137.	2.2	40
56	Classification and Subtypes of Vascular Dementia. <i>International Psychogeriatrics</i> , 2003, 15, 27-37.	0.6	39
57	Five-Year Outcome of Cholinergic Treatment of Alzheimer's Disease: Early Response Predicts Prolonged Time until Nursing Home Placement, but Does Not Alter Life Expectancy. <i>Dementia and Geriatric Cognitive Disorders</i> , 2004, 18, 197-206.	0.7	38
58	Increased lipid and lipoprotein concentrations in anorexia nervosa: A systematic review and meta-analysis. <i>International Journal of Eating Disorders</i> , 2019, 52, 611-629.	2.1	38
59	Hourly variability of cerebrospinal fluid biomarkers in Alzheimer's disease subjects and healthy older volunteers. <i>Neurobiology of Aging</i> , 2012, 33, 831.e1-831.e9.	1.5	36
60	Prodromal cognitive signs of dementia in 85-year-olds using four sources of information. <i>Neurology</i> , 2005, 65, 1894-1900.	1.5	34
61	A systematic review of studies on the faecal microbiota in anorexia nervosa: future research may need to include microbiota from the small intestine. <i>Eating and Weight Disorders</i> , 2018, 23, 399-418.	1.2	33
62	Zinc induces neurofilament phosphorylation independent of p70 S6 kinase in N2a cells. <i>NeuroReport</i> , 2005, 16, 591-595.	0.6	31
63	Comorbid depression as a negative predictor of weight gain during treatment of anorexia nervosa: A systematic scoping review. <i>European Eating Disorders Review</i> , 2020, 28, 605-619.	2.3	30
64	Treatment of Aggressive Behavior in Dementia With the Anticonvulsant Topiramate: A Retrospective Pilot Study. <i>International Psychogeriatrics</i> , 2003, 15, 307-309.	0.6	29
65	Increased frequency of a new polymorphism in the cell division cycle 2 (cdc2) gene in patients with Alzheimer's disease and frontotemporal dementia. <i>Neuroscience Letters</i> , 2003, 340, 69-73.	1.0	28
66	HPA axis activation determined by the CRH challenge test in patients with few versus multiple episodes of treatment-refractory depression. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2004, 254, 349-355.	1.8	27
67	Depressive symptoms and white matter changes in patients with dementia. <i>International Journal of Geriatric Psychiatry</i> , 2006, 21, 119-125.	1.3	27
68	Informed consent in dementia research. Legislation, theoretical concepts and how to assess capacity to consent. <i>European Geriatric Medicine</i> , 2010, 1, 58-63.	1.2	26
69	Pathophysiological aspects of frontotemporal dementia—emphasis on cytoskeleton proteins and autoimmunity. <i>Mechanisms of Ageing and Development</i> , 2001, 122, 1923-1935.	2.2	24
70	Frontotemporal dementia—A brief review. <i>Mechanisms of Ageing and Development</i> , 2006, 127, 180-187.	2.2	23
71	Lifetime burden of mood swings and activation of brain norepinephrine turnover in patients with treatment-refractory depressive illness. <i>Journal of Affective Disorders</i> , 2003, 74, 185-189.	2.0	22
72	An integrated multi-study analysis of intra-subject variability in cerebrospinal fluid amyloid- β concentrations collected by lumbar puncture and indwelling lumbar catheter. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 53.	3.0	22

#	ARTICLE	IF	CITATIONS
73	Low Serum Potassium in Mid Life Associated with Decreased Cerebrospinal Fluid A β ²⁴² in Late Life. Alzheimer Disease and Associated Disorders, 2006, 20, 30-36.	0.6	20
74	Cognitive improvement following weight gain in patients with anorexia nervosa: A systematic review. European Eating Disorders Review, 2021, 29, 402-426.	2.3	20
75	Dialectical Behaviour Therapy Improves Emotion Dysregulation Mainly in Binge Eating Disorder and Bulimia Nervosa: A Systematic Review and Meta-Analysis. Journal of Personalized Medicine, 2021, 11, 931.	1.1	20
76	A Systematic Review and Meta-Analysis Finds Increased Blood Levels of All Forms of Ghrelin in Both Restricting and Binge-Eating/Purging Subtypes of Anorexia Nervosa. Nutrients, 2021, 13, 709.	1.7	19
77	Proteomics for drug target discovery. Chemometrics and Intelligent Laboratory Systems, 2004, 73, 47-53.	1.8	18
78	Prediction of Mild Cognitive Impairment that Evolves into Alzheimer's Disease Dementia within Two Years using a Gene Expression Signature in Blood: A Pilot Study. Journal of Alzheimer's Disease, 2013, 35, 611-621.	1.2	18
79	Evaluation of the Glycine Transporter Inhibitor Org 25935 as Augmentation to Cognitive-Behavioral Therapy for Panic Disorder. Journal of Clinical Psychiatry, 2012, 73, 647-653.	1.1	18
80	Relationship between depressive symptomatology and the subcortical brain syndrome in dementia. International Journal of Geriatric Psychiatry, 2002, 17, 774-778.	1.3	17
81	The pattern of cognitive symptoms predicts time to dementia onset. Alzheimer's and Dementia, 2009, 5, 199-206.	0.4	16
82	Biological Correlates of Clinical Subgroups of Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2002, 14, 191-197.	0.7	13
83	Cognitive Function in Adults with Enduring Anorexia Nervosa. Nutrients, 2021, 13, 859.	1.7	12
84	Sexual function and dysfunction among women with anorexia nervosa: A systematic scoping review. International Journal of Eating Disorders, 2020, 53, 1377-1399.	2.1	12
85	BMI at Discharge from Treatment Predicts Relapse in Anorexia Nervosa: A Systematic Scoping Review. Journal of Personalized Medicine, 2022, 12, 836.	1.1	12
86	Oral d-fenfluramine test in treatment-refractory depression. Journal of Affective Disorders, 2000, 57, 201-208.	2.0	11
87	Treatment studies with cannabinoids in anorexia nervosa: a systematic review. Eating and Weight Disorders, 2021, 26, 407-415.	1.2	11
88	CSF biomarker utilisation and ethical considerations of biomarker assisted diagnosis and research in dementia: perspectives from within the European Alzheimer's Disease Consortium (EADC). Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 124-125.	0.9	8
89	Effect of diagnostic criteria on prevalence of frontotemporal dementia in the elderly. Alzheimer's and Dementia, 2015, 11, 425-433.	0.4	8
90	Objective Measurement of the Alertness Level in Dementia. Dementia and Geriatric Cognitive Disorders, 2003, 15, 212-217.	0.7	7

#	ARTICLE	IF	CITATIONS
91	Weight Gain in Adults with Avoidant/Restrictive Food Intake Disorder Compared to Restrictive Anorexia Nervosa—Pilot Findings from a Longitudinal Study. <i>Nutrients</i> , 2021, 13, 871.	1.7	7
92	Longitudinal EEG Findings in Dementia Related to the Parietal Brain Syndrome and the Degree of Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 1998, 9, 199-204.	0.7	6
93	EDRF transcripts and diagnosis of variant Creutzfeldt-Jakob disease. <i>Lancet, The</i> , 2001, 357, 2069-2070.	6.3	6
94	Alzheimer Biomarkers and Clinical Alzheimer Disease were Not Associated with Increased Cerebrovascular Disease in a Memory Clinic Population. <i>Current Alzheimer Research</i> , 2014, 11, 40-46.	0.7	6
95	Study protocol of comprehensive risk evaluation for anorexia nervosa in twins (CREAT): a study of discordant monozygotic twins with anorexia nervosa. <i>BMC Psychiatry</i> , 2020, 20, 507.	1.1	6
96	Inpatient Weight Restoration Treatment Is Associated with Decrease in Post-Meal Anxiety. <i>Journal of Personalized Medicine</i> , 2021, 11, 1079.	1.1	6
97	A systematic review of blood-based serotonergic biomarkers in Bulimia Nervosa. <i>Psychiatry Research</i> , 2019, 279, 155-171.	1.7	5
98	Potential shortcomings in current studies on the effect of intranasal oxytocin in Anorexia Nervosa and healthy controls - A systematic review and meta-analysis. <i>Psychopharmacology</i> , 2020, 237, 2891-2903.	1.5	5
99	Case report: cognitive performance in an extreme case of anorexia nervosa with a body mass index of 7.7. <i>BMC Psychiatry</i> , 2020, 20, 284.	1.1	5
100	Estimating the Effect of Motivational Interventions in Patients with Eating Disorders: A Systematic Review and Meta-Analysis. <i>Journal of Personalized Medicine</i> , 2022, 12, 577.	1.1	5
101	Cortisol, Depression, and Anxiety Levels Before and After Short-Term Intensive Nutritional Stabilization in Patients With Severe Anorexia Nervosa. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	5
102	A randomised trial of the effect of the glycine reuptake inhibitor Org 25935 on cognitive performance in healthy male volunteers. <i>Human Psychopharmacology</i> , 2014, 29, 163-171.	0.7	4
103	Explanatory Factors for Disease-Specific Health-Related Quality of Life in Women with Anorexia Nervosa. <i>Journal of Clinical Medicine</i> , 2021, 10, 1592.	1.0	4
104	Anorexia Nervosa: Reduction in Depression during Inpatient Treatment Is Closely Related to Reduction in Eating Disorder Psychopathology. <i>Journal of Personalized Medicine</i> , 2022, 12, 682.	1.1	4
105	Negative Neurofilament Light and Tau Immunostaining in Frontotemporal Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2004, 17, 346-349.	0.7	3
106	Cerebrospinal Fluid Biomarkers in Diagnosing Alzheimer's Disease in Clinical Practice: An Illustration with 3 Case Reports. <i>Case Reports in Neurology</i> , 2010, 2, 5-11.	0.3	3
107	SYMPTOMATOLOGICAL CHARACTERISTICS DISTINGUISH BETWEEN FRONTOTEMPORAL DEMENTIA AND VASCULAR DEMENTIA WITH A DOMINANT FRONTAL LOBE SYNDROME. <i>International Journal of Geriatric Psychiatry</i> , 1997, 12, 656-661.	1.3	3
108	Why Do Women with Eating Disorders Decline Treatment? A Qualitative Study of Barriers to Specialized Eating Disorder Treatment. <i>Nutrients</i> , 2021, 13, 4033.	1.7	3

#	ARTICLE	IF	CITATIONS
109	Anorexia Nervosa and Motivation for Behavioral Change - Can it be Enhanced?. Journal of Psychology & Clinical Psychiatry, 2017, 8, .	0.0	2
110	On motivation as a Target for Intervention in Anorexia Nervosa. Archives in Neurology & Neuroscience, 2019, 5, .	0.1	1
111	Frontotemporal dementia - Clinical and pathophysiological aspects. Nordic Journal of Psychiatry, 2000, 54, 149-150.	0.7	0
112	P3-241 Zinc induces phosphorylation of neurofilament proteins in mouse N2A neuroblastoma cells. Neurobiology of Aging, 2004, 25, S423.	1.5	0
113	The use of indexes in the interpretation of cerebrospinal fluid analyses. Neurobiology of Aging, 2010, 31, 1654.	1.5	0
114	Dysbiosis of the Microbiota in Anorexia Nervosa: Pathophysiological Implications. , 2019, , .		0
115	A Brief Review of the Biology of Anorexia Nervosa. Journal of Psychology & Clinical Psychiatry, 2015, 4, .	0.0	0
116	The Diagnostic Work-Up of Eating Disorders. Journal of Psychology & Clinical Psychiatry, 2015, 4, .	0.0	0
117	Validating the Danish version of the Eating Disorder Quality of Life Scale (EDQLS) in anorexia nervosa. Eating and Weight Disorders, 2022, , 1.	1.2	0